Middletown Life

Author: Zealand Pharma

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity

March 5, 2026
Zealand Pharma convenes its Annual General Meeting 2026

February 19, 2026
Zealand Pharma Announces Financial Results for the Full Year 2025

February 19, 2026
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830

February 18, 2026
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

February 13, 2026